Cutaneous metastases from internal malignancies are uncommon and occur in 0.6%–10.4% of all patients with cancer. In most cases, cutaneous metastases develop after the initial diagnosis of the primary internal malignancy and late in the course of the disease. Skin tumors are infrequent in Asian population and cutaneous metastases are quite rare. Cutaneous metastases carry a poor prognosis with average survival of few months. In the present five-year study 1924 malignant tumors were screened which included only nine cases of cutaneous metastatic deposits. A wide range of site and clinical presentations including nodules, plaques, and ulcers was noted. Histopathological findings were significant and corresponded with the primary internal malignancy. Cutaneous metastases from breast carcinoma (44.4%) were the most common finding followed by non-Hodgkin lymphoma and renal cell carcinoma (22.2% each) and carcinoma cervix (11.1%). The aim of our study is to classify the cutaneous metastases and to evaluate their clinicopathologic and immunohistochemical correlation with the primary tumor. 1. Introduction Cutaneous metastasis can be defined as the spread of a tumor from the site of its primary origin to the skin [1]. Skin metastasis may be the first sign of an advanced cancer or an indicator of cancer recurrence [2, 3]. Up to 9% of patients with cancer may develop skin metastases, while metastasis may develop more than 10 years after initial cancer diagnosis [3]. A wide morphologic spectrum of clinical appearances has been described in cutaneous metastases including nodules, plaques, papules, tumors, and ulcers [4]. While carcinomas are the most common type of cancer to metastasize, sarcomas, lymphomas, and leukemias also represent a substantial percentage of all skin metastases [5]. The relative frequencies of metastatic skin disease in each sex correlate with the frequency of different types of primary cancer. Thus women with the skin metastases have the following distribution in decreasing order of primary malignancies: breast, ovary, oral cavity, lung, and large intestine. In men, the distribution is as follows: lung, large intestine, oral cavity, kidney, breast, esophagus, pancreas, stomach, and liver [4]. Generally, cutaneous metastases herald a poor prognosis with average survival time of a few months. 2. Materials and Method In the present five-year study, patients diagnosed with an internal malignancy including hematolymphoid neoplasms, registered between March 2009 and March 2014 in the Pathology Department, were consecutively screened. The H&E
References
[1]
C. Y. B. Wong, M. A. Helm, T. N. Helm, and N. Zeitouni, “Patterns of skin metastases: a review of 25 years, experience at a single cancer center,” International Journal of Dermatology, vol. 53, pp. 55–60, 2014.
[2]
P. S. Spencer and T. N. Helm, “Skin metastases in cancer patients,” Cutis, vol. 39, no. 2, pp. 119–121, 1987.
[3]
R. A. Schwartz, Skin Cancer: Recognition and Management, Blackwell, Malden, Mass, USA, 2nd edition, 2008.
[4]
I. Alcaraz, L. Cerroni, A. Rütten, H. Kutzner, and L. Requena, “Cutaneous metastases from internal malignancies: a clinicopathologic and immunohistochemical review,” The American Journal of Dermatopathology, vol. 34, no. 4, pp. 347–393, 2012.
[5]
R. A. Schwartz, “Cutaneous metastatic disease,” Journal of the American Academy of Dermatology, vol. 33, no. 2, pp. 161–182, 1995.
[6]
D. P. Lookingbill, N. Spangler, and K. F. Helm, “Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients,” Journal of the American Academy of Dermatology, vol. 29, no. 2, pp. 228–236, 1993.
[7]
U. Gul, A. Kihc, M. Gonul, et al., “Spectrum of cutaneous metastases in 1287 cases of internal malignancies: a study from Turkey,” Acta Dermato-Venereologica, vol. 87, pp. 160–162, 2007.
[8]
M. H. Brownstein and E. B. Helwig, “Patterns of cutaneous metastasis,” Archives of Dermatology, vol. 105, no. 6, pp. 862–868, 1972.
[9]
B. Basu and S. Mukherjee, “Cutaneous metastasis in cancer of the uterine cervix: a case report and review of the literature,” Journal of the Turkish German Gynecology Association, vol. 14, no. 3, pp. 174–177, 2013.
[10]
L. W. Brady, E. A. O'Neill, and S. H. Farber, “Unusual sites of metastases,” Seminars in Oncology, vol. 4, no. 1, pp. 59–64, 1977.
[11]
P. Sountoulides, L. Metaxa, and L. Cindolo, “Atypical presentations and rare metastatic sites of renal cell carcinoma: a review of case reports,” Journal of Medical Case Reports, vol. 5, article 429, 2011.
[12]
R. Bansal and R. Naik, “A study of 70 cases of cutaneous metastases from internal carcinoma,” Journal of the Indian Medical Association, vol. 96, no. 1, pp. 10–12, 1998.
[13]
M. R. Wick, P. E. Swanson, J. H. Ritter, and J. F. Fitzgibbon, “The immunohistology of cutaneous neoplasia: a practical perspective,” Journal of Cutaneous Pathology, vol. 20, no. 6, pp. 481–497, 1993.
[14]
S. Saeed, C. A. Keehn, and M. B. Morgan, “Cutaneous metastasis: a clinical, pathological, and immunohistochemical appraisal,” Journal of Cutaneous Pathology, vol. 31, no. 6, pp. 419–430, 2004.
[15]
H. S. Qureshi, A. H. Ormsby, M. W. Lee, R. J. Zarbo, and C. K. Ma, “The diagnostic utility of p63, CK5/6, CK 7, and CK 20 in distinguishing primary cutaneous adnexal neoplasms from metastatic carcinomas,” Journal of Cutaneous Pathology, vol. 31, no. 2, pp. 145–152, 2004.
[16]
D. Ivan, A. H. Diwan, and V. G. Prieto, “Expression of p63 in primary cutaneous adnexal neoplasms and adenocarcinoma metastatic to the skin,” Modern Pathology, vol. 18, no. 1, pp. 137–142, 2005.
[17]
D. Ivan, J. W. Nash, V. G. Prieto et al., “Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin,” Journal of Cutaneous Pathology, vol. 34, no. 6, pp. 474–480, 2007.
[18]
K. R. Bauer, M. Brown, R. D. Cress, C. A. Parise, and V. Caggiano, “Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype,” Cancer, vol. 109, no. 9, pp. 1721–1728, 2007.
